These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23391144)

  • 1. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.
    Pastorelli F; Derenzini E; Plasmati R; Pellegrini C; Broccoli A; Casadei B; Argnani L; Salvi F; Pileri S; Zinzani PL
    Leuk Lymphoma; 2013 Oct; 54(10):2318-21. PubMed ID: 23391144
    [No Abstract]   [Full Text] [Related]  

  • 2. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
    Oak E; Bartlett NL
    Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
    Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
    Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
    Gandhi MD; Evens AM; Fenske TS; Hamlin P; Coiffier B; Engert A; Moskowitz AJ; Ghosh N; Petrich AM; Lomasney J; Chadburn A; Wood GS; Salva K; Nardone B; Trifilio SM; Raisch DW; West DP; Gordon LI; Winter JN
    Blood; 2014 May; 123(18):2895-7. PubMed ID: 24786458
    [No Abstract]   [Full Text] [Related]  

  • 5. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy.
    Mukkada S; Metzger ML; Santiago T; Wolf J
    J Pediatric Infect Dis Soc; 2019 Sep; 8(4):371-373. PubMed ID: 30423147
    [No Abstract]   [Full Text] [Related]  

  • 9. Brentuximab vedotin: axonal microtubule's Apollyon.
    Mariotto S; Ferrari S; Sorio M; Benedetti F; Tridente G; Cavallaro T; Gajofatto A; Monaco S
    Blood Cancer J; 2015 Aug; 5(8):e343. PubMed ID: 26314985
    [No Abstract]   [Full Text] [Related]  

  • 10. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
    Younes A
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
    [No Abstract]   [Full Text] [Related]  

  • 13. Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events.
    Clifford K; Copeland A; Knutzen G; Samuelson E; Grove L; Schiavo K
    Clin J Oncol Nurs; 2018 Aug; 22(4):E103-E114. PubMed ID: 30035778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
    Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
    Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
    Monjanel H; Deville L; Ram-Wolff C; Venon MD; Franchi P; Benet C; de Kerviler E; Malphettes M; Thieblemont C; Brice P
    Br J Haematol; 2014 Jul; 166(2):306-8. PubMed ID: 24673542
    [No Abstract]   [Full Text] [Related]  

  • 16. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K
    Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV; Bartlett NL
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
    [No Abstract]   [Full Text] [Related]  

  • 20. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.
    Sasse S; Rothe A; Goergen H; Eichenauer DA; Lohri A; Kreher S; Jäger U; Bangard C; Kuhnert G; Böll B; von Tresckow B; Engert A
    Leuk Lymphoma; 2013 Oct; 54(10):2144-8. PubMed ID: 23402268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.